MACROD1

ADP-ribose glycohydrolase MACROD1 · Q9BQ69 · MACROD1 on Sugi Atlas →

4,201 patent compounds predicted against MACROD1, 3,965 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diadenosine Tetraphosphate (SCHEMBL849869)	0.93	1/20
SCHEMBL1744586	0.93	1/20
SCHEMBL2934890	0.93	1/20
Diadenosine Tetraphosphate (SCHEMBL4069414)	0.93	1/20
SCHEMBL4357990	0.93	1/20
Diadenosine Tetraphosphate (SCHEMBL4363130)	0.93	1/20
Adenosine Triphosphate (SCHEMBL926531)	0.89	1/20
Adenosine Triphosphate (SCHEMBL926534)	0.89	1/20
Adenosine Triphosphate (SCHEMBL8979)	0.88	1/20
Adenosine Triphosphate (SCHEMBL8980)	0.88	1/20
SCHEMBL376008	0.88	1/20
SCHEMBL376009	0.88	1/20
Adenosine Triphosphate (SCHEMBL468214)	0.88	1/20
Adenosine Triphosphate (SCHEMBL889293)	0.88	1/20
Adenosine Triphosphate (SCHEMBL2227081)	0.88	1/20
Adenosine Triphosphate (SCHEMBL4362224)	0.88	1/20
SCHEMBL4366441	0.88	1/20
Adenosine Triphosphate (SCHEMBL28356)	0.86	1/20
Adenosine Triphosphate (SCHEMBL28358)	0.86	1/20
Atpgammas (SCHEMBL77440)	0.86	1/20

Clinical trials — most relevant to MACROD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)	PHASE3	COMPLETED
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Role of Genetic Factors in the Development of Lung Disease	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Prospective Validation of Prostate Biomarkers for Repeat Biopsy	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)	nan	COMPLETED
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab	nan	COMPLETED
Genetic Studies of X-linked Lymphoproliferative Disease	nan	COMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MACROD1 binder may also engage these)

Protein	Name	Similarity
Q922B1	—	1.000	Q922B1 →
Q2KHU5	—	1.000	Q2KHU5 →
Q8K4G6	—	0.994	Q8K4G6 →
D3ZEY4	—	0.986	D3ZEY4 →
Q14147	—	0.986	Q14147 →
KDM1A	Lysine-specific histone demethylase 1A	0.986	landscape →
Q8K596	—	0.985	Q8K596 →
P23249	—	0.985	P23249 →
KAT8	Histone acetyltransferase KAT8	0.985	landscape →
Q9H4I3	—	0.985	Q9H4I3 →
Q68FX9	—	0.984	Q68FX9 →
Q8BJM7	—	0.984	Q8BJM7 →
Q6P5E8	—	0.984	Q6P5E8 →
Q5NTH4	—	0.984	Q5NTH4 →
B7ZC32	—	0.984	B7ZC32 →
Q9Y4C4	—	0.984	Q9Y4C4 →
Q6PGC1	—	0.984	Q6PGC1 →
Q9NY93	—	0.984	Q9NY93 →
Q9Y4B4	—	0.983	Q9Y4B4 →
Q5BJS0	—	0.983	Q5BJS0 →
Q6ZGP8	—	0.983	Q6ZGP8 →
Q9SJ05	—	0.983	Q9SJ05 →
Q9UQ90	—	0.983	Q9UQ90 →
Q5R607	—	0.983	Q5R607 →
P12617	—	0.983	P12617 →
Q9DBV3	—	0.983	Q9DBV3 →
Q3TIU4	—	0.983	Q3TIU4 →
O35071	—	0.983	O35071 →
Q6YYZ1	—	0.983	Q6YYZ1 →
ENGASE	Cytosolic endo-beta-N-acetylglucosaminidase	0.983	landscape →